TY  - GEN
AU  - Tocoian,A
AU  - Buchan,P
AU  - Kirby,H
AU  - Soranson,J
AU  - Zamacona,M
AU  - Walley,R
AU  - Mitchell,N
AU  - Esfandiari,E
AU  - Wagner,F
AU  - Oliver,R
TI  - First-in-human trial of the safety, pharmacokinetics and immunogenicity of a PEGylated anti-CD40L antibody fragment (CDP7657) in healthy individuals and patients with systemic lupus erythematosus
SN  - 1477-0962
PY  - 2016///0531
KW  - Adult
KW  - CD40 Ligand
KW  - antagonists & inhibitors
KW  - Cohort Studies
KW  - Dose-Response Relationship, Immunologic
KW  - Double-Blind Method
KW  - Female
KW  - Humans
KW  - Immunoglobulin Fab Fragments
KW  - administration & dosage
KW  - Immunoglobulin Fragments
KW  - Lupus Erythematosus, Systemic
KW  - drug therapy
KW  - Male
KW  - Middle Aged
KW  - Polyethylene Glycols
KW  - Treatment Outcome
N1  - Publication Type: Clinical Trial, Phase I; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1177/0961203315574558
ER  -